Management of chemotherapy-associated febrile neutropenia
نویسندگان
چکیده
منابع مشابه
Chemotherapy induced febrile neutropenia: management and prevention.
chemotherapy remains the cornerstone of cancer therapy. In most cases bone marrow suppression represents the doselimiting toxicity of these drugs. Druginduced DNA damage at the level of bone marrow progenitor cells results in a fall in circulating neutrophil count. Patients with neutropenia are at increased risk of infection and sepsis.1 The timing of neutropenia is generally predictable; it ty...
متن کاملManagement of Febrile Neutropenia
Bacterial Pathogens Bacteria are the predominant organisms. In the late 1950’s/early 1960’s Gram+ve organisms were the commonest, particularly Staphylococcus aureus. The late 1960’s/early 1970’s were typified by Gram-ve of gastrointestinal tract origin, particularly Escherischia coli, Klebsiella spp and Pseudomonas spp. By the 1990’s Staphylococcus spp including coagulase negative organisms, St...
متن کاملManagement of febrile neutropenia: ESMO clinical recommendations.
Despite major advances in prevention and treatment, febrile neutropenia (FN) remains one of the most feared complications of cancer chemotherapy, and is a major cause of morbidity, healthcare resource use, and results in delays and dose reductions in chemotherapy which compromise efficacy. Mortality from FN has diminished steadily but remains significant. Overall mortality rates are 5% in patie...
متن کاملFebrile neutropenia in chemotherapy treated small-cell lung cancer patients
BACKGROUND Chemotherapy with platinum agent and etoposide for small-cell lung cancer (SCLC) is supposed to be associated with intermediate risk (10-20%) of febrile neutropenia. Primary prophylaxis with granulocyte colony-stimulating factors (G-CSFs) is not routinely recommended by the treatment guidelines. However, in clinical practice febrile neutropenia is often observed with standard etoposi...
متن کاملGarenoxacin Prophylaxis for Febrile Neutropenia after Chemotherapy in Hematological Malignancies
Background: Febrile neutropenia is one of the most serious adverse events in patients with hematological malignancies and chemotherapy. The routine use of fluoroquinolone prophylaxis in patients with hematological malignancies is controversial. Therefore, we prospectively evaluated the efficacy and safety of prophylactic use of garenoxacin for febrile neutropenia. Patients and Methods: Consecut...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: British Journal of Cancer
سال: 2009
ISSN: 0007-0920,1532-1827
DOI: 10.1038/sj.bjc.6605272